Related Experiment Video

Updated: Jun 4, 2026

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Propranolol for the treatment of orbital infantile hemangiomas

Gretta Fridman1, Eric Grieser, Robert Hill

  • 1Department of Ophthalmology, University of South Florida College of Medicine, Tampa, Florida, USA.

Ophthalmic Plastic and Reconstructive Surgery
|February 2, 2011
PubMed

Insights

Oral propranolol effectively treats orbital infantile hemangiomas in infants, significantly reducing tumor size in 80% of cases with no major adverse events. This offers a promising therapeutic option for this condition.

Area of Science:

  • Ophthalmology
  • Pediatric Dermatology
  • Pharmacology

Background:

  • Orbital infantile hemangiomas are common benign vascular tumors in infants.
  • Treatment options for orbital infantile hemangiomas have historically been limited.
  • Systemic propranolol has emerged as a potential therapeutic agent.

Observation:

  • A retrospective case series of 5 infants with orbital infantile hemangiomas was conducted.
  • Infants were treated with oral propranolol, with dosages varying by center.
  • The average treatment duration was 7.1 months.

Findings:

  • Oral propranolol resulted in significant size reduction of orbital infantile hemangiomas in 4 out of 5 (80%) infants.
  • One patient experienced minimal improvement.
  • No significant adverse events were reported during the treatment period.

Implications:

  • Systemic propranolol demonstrates efficacy and safety for treating orbital infantile hemangiomas.
  • This treatment may offer a non-invasive alternative for managing these pediatric vascular lesions.
  • Further research is warranted to establish optimal dosing and long-term outcomes.
Abstract

More Related Videos

A Neonatal Rodent Model of Retroorbital Vein Injection04:39

A Neonatal Rodent Model of Retroorbital Vein Injection

Published on: February 23, 2024

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...